Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the Chances of Approval and Market Potential for Radius Health's (RDUS) Abaloparatide-SC for Postmenopausal Women with Osteoporosis

Ticker(s): RDUS, AMGN, LLY

Who's the expert?

An endocrinologist or other doctor with specialized training in osteoporosis, who has knowledge of the trials for abaloparatide-SC and other drugs in the space. He or she will be someone who treats osteoporosis patients, and understands the regulatory processes and current competitive environment.

Interview Questions
Q1.

Can you describe your experience treating patients, and current methods you use for osteoporosis patients in your practice? 

Added By: pjloria
Q2.

How many osteoporosis patients do you see? What leads a patient to seek treatment, and what are the costs of not treating osteoporosis? 

Added By: pjloria
Q3.

Radius recently announced pre-specified subgroup analyses from its Phase 3 ACTIVE trial, and has made a number of other presentations on their Phase 3 data. Can you discuss the results of these trials, and their implications?

Added By: pjloria
Q4.

Given the current information, what chance does Radius stand to receive approval for its two outstanding authorization applications for the EMA and the FDA?

Added By: pjloria
Q5.

Assuming it gets approved, what percentage of existing patients do you expect to switch to abaloparatide-SC? What percentage of new patients will you prescribe abaloparatide-SC? Will the drug's approval have an affect on any patients who may not currently be seeking treatment? 

Added By: pjloria
Q6.

Can you discuss the differences in terms of safety, efficacy, and pricing between abaloparatide-SC, Lilly's generic FORTEO, and Amgen's romosozumab? How much market share do you expect each to attain assuming abaloparatide-SC and romosozumab are approved? 

Added By: pjloria
Q7.

FORTEO and abaloparatide-SC are daily injections, whereas romosozumab is injected once a month. How will this affect the popularity of each drug?  Do these differences suggest romosozumab fits a niche market within osteoporosis?

Added By: pjloria
Q8.

Would efficacy or price be more important to you and your patients in choosing a treatment option between these three? 

Added By: pjloria
Q9.

Can you discuss the most recent data from Amgen's Phase 3 BRIDGE study on romosozumab in men with osteoporosis? 

Added By: pjloria
Q10.

If Radius received approval for abaloparatide-SC in treatment of postmenopausal women with osteoporosis, would they use this as a basis to try for an expanded indication covering men with osteoporosis? If so, do you think they would be successful, and how much of that market could they win? 

Added By: pjloria
Q11.

Please explain the mode of action and can you compare the benefit vs other products including 
1. Decrease in fracture risk at the femoral neck and lumbar spine 
2. Increase in BMD vs competitors

Added By: drsug

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.